Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy.
Perrone F, Pecci F, Maffezzoli M, Giudice GC, Cognigni V, Mazzaschi G, Cantini L, Santamaria L, Paoloni F, Bruno Rocchi ML, Coriano' M, Acunzo A, Quaini F, Tiseo M, Kamal SS, Berardi R, Buti S. Perrone F, et al. Among authors: quaini f. Immunotherapy. 2024;16(13):859-868. doi: 10.1080/1750743X.2024.2377953. Epub 2024 Aug 6. Immunotherapy. 2024. PMID: 39105618
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors.
Perrone F, Favari E, Maglietta G, Verzè M, Pluchino M, Minari R, Sabato R, Mazzaschi G, Ronca A, Rossi A, Cortellini A, Pecci F, Cantini L, Bersanelli M, Quaini F, Tiseo M, Buti S. Perrone F, et al. Among authors: quaini f. Cancer Immunol Immunother. 2023 Jul;72(7):2127-2135. doi: 10.1007/s00262-023-03398-3. Epub 2023 Feb 24. Cancer Immunol Immunother. 2023. PMID: 36828963 Free PMC article.
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity.
Bersanelli M, Gnetti L, Pilato FP, Varotti E, Quaini F, Campanini N, Rapacchi E, Camisa R, Carbognani P, Silini EM, Rusca M, Leonardi F, Maestroni U, Rizzo M, Brunelli M, Buti S, Ampollini L. Bersanelli M, et al. Among authors: quaini f. Explor Target Antitumor Ther. 2023;4(4):743-756. doi: 10.37349/etat.2023.00165. Epub 2023 Aug 31. Explor Target Antitumor Ther. 2023. PMID: 37720351 Free PMC article.
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score.
Mazzaschi G, Lazzarin A, Santoni M, Trentini F, Giorgi U, Brighi N, Tommasi C, Puglisi S, Caffo O, Kinspergher S, Mennitto A, Cattrini C, Verzoni E, Rametta A, Stellato M, Malgeri A, Roviello G, Silini EM, Rescigno P, Rebuzzi SE, Fornarini G, Quaini F, Giudice GC, Banna GL, Buti S. Mazzaschi G, et al. Among authors: quaini f. Front Biosci (Elite Ed). 2023 Jul 28;15(3):20. doi: 10.31083/j.fbe1503020. Front Biosci (Elite Ed). 2023. PMID: 37743233 Free article.
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations.
Maffezzoli M, Santoni M, Mazzaschi G, Rodella S, Lai E, Maruzzo M, Basso U, Bimbatti D, Iacovelli R, Anghelone A, Fiala O, Rebuzzi SE, Fornarini G, Lolli C, Massari F, Rosellini M, Mollica V, Nasso C, Acunzo A, Silini EM, Quaini F, De Filippo M, Brunelli M, Banna GL, Rescigno P, Signori A, Buti S. Maffezzoli M, et al. Among authors: quaini f. Clin Exp Metastasis. 2024 Apr;41(2):117-129. doi: 10.1007/s10585-024-10266-6. Epub 2024 Feb 16. Clin Exp Metastasis. 2024. PMID: 38363410 Free PMC article.
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors.
Mazzaschi G, Perrone F, Maglietta G, Favari E, Verzè M, Pluchino M, Minari R, Pecci F, Gnetti L, Campanini N, Silini EM, De Filippo M, Maffezzoli M, Giudice GC, Testi I, Tiseo M, Quaini F, Buti S. Mazzaschi G, et al. Among authors: quaini f. J Immunother. 2024 Nov-Dec 01;47(9):388-394. doi: 10.1097/CJI.0000000000000534. Epub 2024 Jul 11. J Immunother. 2024. PMID: 38989743 Free PMC article.
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Balbi M, Mazzaschi G, Leo L, Moron Dalla Tor L, Milanese G, Marrocchio C, Silva M, Mura R, Favia P, Bocchialini G, Trentini F, Minari R, Ampollini L, Quaini F, Roti G, Tiseo M, Sverzellati N. Balbi M, et al. Among authors: quaini f. J Thorac Imaging. 2025 Jan 1;40(1):e0801. doi: 10.1097/RTI.0000000000000801. J Thorac Imaging. 2025. PMID: 39188157 Free PMC article.
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns of acquired resistance to immunotherapy in patients with NSCLC.
Mazzaschi G, Marrocchio C, Moron Dalla Tor L, Leo L, Balbi M, Milanese G, Adebanjo GAR, Lorusso B, Monica G, Pluchino M, Minari R, D'Agnelli S, Cardinale E, Perrone F, Bordi P, Leonetti A, Ledda RE, Silva M, Buti S, Roti G, Bettati S, Quaini F, Tiseo M, Sverzellati N. Mazzaschi G, et al. Among authors: quaini f. Clin Cancer Res. 2024 Dec 13. doi: 10.1158/1078-0432.CCR-24-1926. Online ahead of print. Clin Cancer Res. 2024. PMID: 39670974
CD26 Is Differentially Expressed throughout the Life Cycle of Infantile Hemangiomas and Characterizes the Proliferative Phase.
Lorusso B, Nogara A, Fioretzaki R, Corradini E, Bove R, Roti G, Gherli A, Montanaro A, Monica G, Cavazzini F, Bonomini S, Graiani G, Silini EM, Gnetti L, Pilato FP, Cerasoli G, Quaini F, Lagrasta CAM. Lorusso B, et al. Among authors: quaini f. Int J Mol Sci. 2024 Sep 10;25(18):9760. doi: 10.3390/ijms25189760. Int J Mol Sci. 2024. PMID: 39337249 Free PMC article.
166 results